NCT01316237 - A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

January 31, 2012

Conditions

Hepatitis C, Chronic

Interventions

DRUG

GS-6620

GS-6620 tablet, 50 mg QD

DRUG

GS-6620

GS-6620 tablet, 100 mg QD

DRUG

GS-6620

GS-6620 tablet, 300 mg QD

DRUG

GS-6620

GS-6620 tablet, 100 mg QD, Fasted

DRUG

GS-6620

GS-6620 tablet, 300 mg QD, Fasted

DRUG

GS-6620

GS-6620 tablet, 900 mg QD, Fasted

DRUG

GS-6620 tablet, 450 mg BID

DRUG

GS-6620 tablet

GS-6620 tablet, 900mg , BID

DRUG

GS-6620 tablet

GS-6620 tablet, 900 mg

Trial Locations (13)

19139

CRI Worldwide, Philadelphia

32608

University of Florida - Gainesville, Gainesville

32720

Avail Clinical Research, LLC, DeLand

32803

Orlando Immunology Center, Orlando

32809

Orlando Clinical Research Center, Orlando

63104

Saint Louis University, St Louis

77030

St. Luke Episcopal Hospital, Houston

78215

Alamo Medical Research, San Antonio

84106

Lifetree Clinical Research, LC, Salt Lake City

90057

Axis Clinical Trials, Los Angeles

92801

Advanced Clinical Research Institute, Anaheim

98418

Charles River Clinical Services Northwest, Tacoma

00927

Fundacion De Investigacion De Diego, San Juan